GEN

Rare Bleeding Disorder, HHT, Treated Successfully with Cancer Drug in Clinical Trial

A clinical trial supported by the National Institutes of Health (NIH) was stopped early after researchers found sufficient evidence that a drug called pomalidomide, which is used to treat bone marrow ...
Science Daily

Clinical trial successfully repurposes cancer drug for hereditary bleeding disorder

A drug approved for treating the blood cancer multiple myeloma may offer a safe and effective way to reduce the risk of severe nosebleeds from a rare but devastating bleeding disorder. Hereditary ...
Morningstar

Diagonal’s First-in-Class Clustering Antibody, DIAG723, Receives Orphan Drug Designation (ODD) from U.S. FDA and an ODD Positive Opinion from EMA for Treatment of Hereditary ...

Treatment strategies for HHT are limited to symptom management as there are currently no approved therapeutics for the disease. “DIAG723 represents a powerful new approach to treating HHT, supported ...

Tectonic Therapeutic to Host Virtual KOL Event and Discussion of TX2100, a Novel Approach for the Treatment of Hereditary Hemorrhagic Telangiectasia, on February 24, 2026

Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”), a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the ...
WFLA News Channel 8

Diagonal Therapeutics to Present New Preclinical Data Demonstrating Disease-Modifying Potential of Receptor Clustering Antibody Approach in HHT at EHA 2025 Congress

Results demonstrate potential of Company’s clustering antibody approach to address key challenges in HHT disease manifestations: restoring ALK1-mediated cellular signaling, preventing and reversing ...
Healthline

Role of Radiology in Osler-Weber-Rendu Syndrome

Medical imaging, like MRI, CT, and ultrasound, plays a vital role in diagnosing HHT, formerly known as Osler-Weber-Rendu syndrome. Imaging can help guide treatment and improve your outlook with HHT.